Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Vical Falls Most in 20 Years on Cancer Drug Trial Results

Vical Inc., the maker of experimental cancer drugs, fell the most in 20 years after saying its melanoma medicine failed to help patients in a clinical trial.

Shares of Vical plunged 57 percent to $1.53 at the close in New York, the biggest one-day drop since March 1993 when the San Diego-based company initially offered shares to the public. Vical said in a statement that it was ending studies of the drug, Allovectin, and would shift its focus toward infectious disease treatments.

Chief Executive Officer Vijay Samant said Allovectin failed to show “statistically significant improvement” in the study of 390 patients with metastatic melanoma. The company had cash and investments of $70 million as of June 30, enough to meet its needs through the end of next year, according to the statement.

“In the coming weeks, we will make the necessary changes to focus resources on our infectious disease vaccine programs and reduce expenses to conserve cash,” Samant said in the statement.

Vical shares had risen 23 percent this year through Aug. 9.

While the company is testing other drugs, it faces “a lack of confidence in Vical’s pipeline candidates and a frustration with the slow pace at which Vical’s DNA-based gene delivery platform has advanced,” Eric Schmidt, a Cowen & Co. analyst in New York, said today in a note to clients.

Download: M&A/Other

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.